Invasive Ductal Carcinoma (IDC)
Invasive Ductal Carcinoma (IDC) is a complex and aggressive form of breast cancer that requires a multidimensional approach to therapy development. Our company is at the forefront of drug and therapy development services for IDC, aiming to provide innovative solutions to combat this aggressive disease.
Overview of Invasive Ductal Carcinoma
Invasive Ductal Carcinoma (IDC), also referred to as infiltrating ductal carcinoma, is a malignant type of breast cancer that originates in the milk ducts and infiltrates the surrounding breast tissue. Annually in the United States, there are an estimated 297,790 new cases of invasive breast cancer. This particular subtype is characterized by the abnormal proliferation and growth of cells, resulting in the formation of tumors that have the potential to metastasize to other parts of the body.
- Rare Subtypes of Invasive Ductal Carcinoma
- Medullary carcinoma
- Metaplastic carcinoma
- Mucinous (or colloid) carcinoma
- Papillary carcinoma
- Tubular carcinoma
Pathogenesis of Invasive Ductal Carcinoma
The development of Invasive Ductal Carcinoma (IDC) can be attributed to various factors, including advancing age, a family history of breast cancer, genetic mutations (such as BRCA1 and BRCA2), hormonal influences (such as early onset of menstruation and late menopause), obesity, and exposure to radiation. However, it is important to note that not all individuals with these risk factors will develop IDC, and conversely, many cases of IDC occur without any identifiable risk factors.
Fig. 1 Timeline of the DCIS-IDC study. (Wang, Jing, et al., 2024)Therapies of Invasive Ductal Carcinoma
- Immunotherapy
ICIs, particularly PD-1 inhibitors, have shown promise in certain subsets of IDC, especially TNBC with PD-L1 overexpression. - Endocrine Therapy
For ER-positive IDC, endocrine therapy is the cornerstone of therapeutics. SERMs (e.g., tamoxifen) and AIs (e.g., anastrozole, letrozole) are used to modulate estrogen signaling and reduce estrogen production.
- Chemotherapy
Chemotherapy is used in various IDC subtypes, including ER-negative and HER2-negative cases. It is often administered before or after surgery to shrink tumors or eliminate residual cancer cells. - HER2-Targeted Therapy
HER2-positive IDC is treated with HER2-targeted therapies, such as trastuzumab and pertuzumab, in combination with chemotherapy. ADCs like T-DM1 and T-DXd have also demonstrated efficacy.
Table 1 Drug studies in Invasive Ductal Carcinoma (IDC). (Wang, Jing, et al., 2024)
| ER-positive breast cancer | |||||
| Aromatase inhibitor | CDK4/6 inhibitor | ||||
| Anastrozole | Letrozole | Exemestane | Abemaciclib | Palbociclib | Ribociclib |
| HER2-positive breast cancer | |||||
| Monoclonal antibody | Tyrosine kinase inhibitor | ||||
| Trastuzumab | Margetuximab | Pertuzumab | Neratinib | Lapatinib | Tucatinib |
Our Services
As a leading company in the field of IDC drug and therapy development, our expertise lies in diagnostics and the development of targeted therapies. We employ advanced diagnostic techniques to accurately identify the molecular subtype of IDC and evaluate the expression levels of various targets, such as ER, HER2, and PD-L1.
Therapy Development Platforms
Animal Models of Invasive Ductal Carcinoma
| Xenograft Model Development | |
| Our company specializes in the development of patient-derived xenograft (PDX) models, where tumor cells or tissues from IDC patients are directly implanted into immunodeficient mice. | |
| Optional Cell Lines | BT20, BT474, MCF-7, MDA-MB-435, SUM1315, ZR-75-1, Others |
| Genetic Engineering Model Development | |
| Transgenic models involve the introduction of specific genes or mutations into animal genomes to induce IDC development. By utilizing tissue-specific promoters, such as MMTV-LTR and C(3)1 promoters, we can achieve targeted expression of oncogenes in the mammary gland. | |
| Optional Transgene | PyMT, SV40, Others |
| Optional Species | Mouse, Rat, Others |
In addition, we also provide other customized animal models to meet diverse needs. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Wang, Jing, et al. "Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance." Signal Transduction and Targeted Therapy 9.1 (2024): 83.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.